News
Press release 08.26.2008 - Semafore Broadens Pipeline with Multi-Targeted Kinase Inhibitors
Press release 08.26.2008 - SF1126, Semafore's PI3 Kinase Inhibitor, Found To Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
Press release 06.04.2008 - Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
Press release 04.14.2008 - Semafore's PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
Press release 02.08.2008 - BIO CEO & Investor Conference 2008: On February 13th Semafore's CEO Ed Jacobs will present at 2:45 pm (ET) at the Waldorf-Astoria in the Park Avenue Suite
Press release 01.29.2008 - Our budding biotech base turning heads (Interview with Semafore's CEO Mr. Edward Jacobs)
Press release 01.09.2008 - Semafore's SF1126 exhibits antitumor and antiangiogenic activity
Press release 01.07.2008 - Semafore and Multiple Myeloma Research Consortium (MMRC) dose first patient in Phase I study of targeted PI3 Kinase (PI3K) inhibitor
Press release 01.03.2008 - Novel anticancer strategy moves from laboratory to clinic: Semafore's SF1126 (Jan. 1 issue of Cancer Research, 2008)
Press release 12.09.2007 - Breast cancer spread by blocking tumor-killing gene, study says. An interview with Dr. Joe Garlich
Press release 10.26.2007 - Semafore's PI3 kinase inhibitor SF1126 is active against tumor and tumor cells and synergizes with standard chemotherapy agents
Press release 08.03.2007 - Semafore Pharmaceuticals names veteran life sciences executive Edward L. Jacobs as Chief Executive Officer
Press release 06.01.2007 - Semafore Pharmaceuticals appoints Dr. Ullrich Schwertschlag Chief Medical Officer
Press release 03.26.2007 - Semafore Pharmaceuticals initiates Phase I clinical trial of PI3K inhibitor SF1126 in solid tumor cancers
Press release 01.05.2007 - Semafore Pharmaceuticals completes $9.5 million financing
Press release 12.05.2006 - Semafore granted nearly one million dollars to study SF1126 in multiple myeloma patients
Press release 12.01.2006 - Semafore Pharmaceuticals announces foundation grant to support upcoming Phase I clinical trial
Press release 08.01.2006 - Semafore Pharmaceuticals adds former Eli Lilly oncology R&D leader Dr. Homer Pearce to SAB
Press release 04.04.2006 - New data presented at AACR meeting further support the advance of Semafore's targeted PI3K inhibitor into Phase I trials
Press release 03.17.2006 - Semafore Pharmaceuticals awarded $2.3 million from State of Indiana; adds leading kinase expert to SAB and strengthens clinical team
Press release 11.17.2005 - Semafore Pharmaceuticals presents new data supporting advancement of its targeted PI3K inhibitor SF1126 into Phase 1 trials
Press release 09.28.2005 - Semafore Pharmaceuticals awarded broad patent covering its PI3K prodrug technology targeting central cell signaling pathway
Press release 04.19.2005 - New data presented at AACR meeting support the clinical potential of Semafore's novel PI3K prodrug
Press release 01.06.2005 - Semafore Pharmaceuticals names Ronald D. Henriksen Chief Executive Officer
Press release 11.22.2004 - Semafore Pharmaceuticals data at AACR conference supporting potential clinical utility of its lead PI3-K inhibitor
Press release 10.04.2004 - Semafore Pharmaceuticals names leading cancer researchers and clinicians to advisory board
Press release 08.26.2004 - New data on Semafore PI3K/PTEN programs confirm potential in multiple cancer indications
Press release 07.22.2004 - Semafore presents animal safety and efficacy data for novel targeted PI3K inhibitor in prostate cancer
Press release 06.29.2004 - Semafore challenges kinase dogma
Press release 06.09.2004 - Semafore presents first in vivo efficacy data for novel targeted PI3K inhibitors
Press release 04.22.2004 - Semafore Pharmaceuticals names Dr. Donald L. Durden Senior Scientific Advisor
Press release 03.17.2004 - From Services To Cancer: Semafore’s Focus Change
Press release 03.01.2004 - Start-Up: Windhover's Review of Emerging Medical Ventures: Semafore Pharmaceuticals Inc. - Modulating the PI3 kinase-PTEN cell-signaling pathway for cancer therapy
Press release 02.05.2004 - Semafore Pharmaceuticals changes name from ComChem and announces addition of senior business and science advisors
Press release 09.08.2003 - BioCentury's Technology Briefing: Yin vs. yang in cancer
Press release 09.03.2003 - ComChem scientific advisor publishes first in vivo efficacy for PI3-Kinase inhibitor against brain cancer, uncovers major cell signal intercept switch
Press release 05.29.2003 - IU, ComChem enter agreement to develop cancer therapies
Press release 04.05.2003 - ComChem is awarded its third National Cancer Institute (NCI) Grant, and announces growth plans for new cancer drug programs
Press release 04.25.2002 - O’Bannon visits high-tech Indianapolis firm to say ‘Tax restructuring = High-paying jobs’
Press release 04.06.2002 - ComChem Technologies, Inc., awarded additional National Cancer Institute grant to develop novel approaches for cancer treatments
Press release 10.04.2001 - ComChem Technologies, Inc., announces the launch of its research laboratories and the Award of a National Cancer Institute Research Grant
|